Lung cancer remains the leading cause of death due to cancer. We do not have effective tools for the early detection of lung cancer, so patients are usually diagnosed at an advanced stage. However, novel therapies based on molecular pathways (such as those involving the epidermal growth factor receptor, anaplastic lymphoma kinase, serine/threonine-protein kinase B-Raf, proto-oncogene tyrosine-protein kinase ROS, c-Met proto-oncogene protein, and RET proto-oncogene protein) are now commonly used in the treatment of lung cancer. In particular, these therapies are considered as first-line treatments for non-small-cell lung cancer. This manuscript outlines previous research on these targeted treatments, focusing on whether they are effective against eye metastasis.
Keywords: Anaplastic Lymphoma Kinase; C-Met Proto-Oncogene Protein; Epidermal Growth Factor Receptor; Lung cancer; Proto-Oncogene Tyrosine-Protein Kinase ROS; RET Proto-Oncogene Protein; Serine/Threonine-Protein Kinase B-Raf.